Bookmark Us
All Food, Diet and Health News 
 Misc. News
 Must-Read News
 Letter to Editor
 Featured Products
 Recalls & Alerts
 Consumer Affair
 Non-food Things
 Health Tips
 Interesting Sites
 Diet & Health
 Heart & Blood
 Body Weight
 Children & Women
 General Health
 Food & Health
 Food Chemicals
 Biological Agents
 Cooking & Packing
 Agri. & Environ.
 Laws & Politics
 General Health
 Drug News
 Mental Health
 Infectious Disease
 Other News
 Food Consumer
 FC News & Others

Search Foodconsumer & Others

Add to Google
Add to My Yahoo
Newsfeed news feed
Su bmit news[release]

More than 100 credit cards available at from, you can pick more than 100 credit cards

Diet & Health : Cancer Last Updated: Apr 20, 2011 - 9:38:09 AM

Arsenic, vitamin A help leukemia patients
By Ben Wasserman
Feb 17, 2009 - 10:04:31 PM

E.mail t.his a.rticle
 P.rinter f.riendly p.age
Get n.ewsletter
Jan 17, 2009 ( -- A new study suggests that patients with cancer of the blood and bone marrow may be treated successfully with a combination of arsenic and vitamin A.

The study published in the Proceedings of the National Academy of Sciences showed that for an average period of 70 months, 80 out of 85 patients treated with arsenic and vitamin A went into complete remission.

Better yet, the patients did not experience any side effects in the lungs and heart and the levels of arsenic in their blood and urine were below the safety limits although they were slightly higher than controls’.

The researchers recommended that the regimen be used to treat patients with blood and bone marrow cancer or acute promyelocytic leukemia.

The Food and Drug approved use of arsenic as medicine to treat people with blood and bone marrow cancer in 2000, Reuters reported. Experts have already suggested vitamin A is also helpful.

FDA press release

September 26, 2000              
Consumer Inquiries:  888-INFO-FDA


The FDA has approved Trisenox (arsenic trioxide) for the treatment of patients with acute promyelocytic leukemia (APL) who have not responded to, or have relapsed following the use of all trans-retinoic acid and anthracycline-based chemotherapy, which is considered first line therapy.

Development of Trisenox was rapid. The drug was approved for marketing only 3 years after the study of the drug was first started in the U.S.

APL is a cancer of the white blood cells. It is characterized by a rapid accumulation of abnormal white blood cells in the bone marrow and blood resulting in anemia, susceptibility to infections, bleeding, and hemorrhage. Patients who have a relapse or who have APL that doesn't respond to first line therapy are currently retreated with all trans-retinoic acid and anthracycline-based chemotherapy or both. Response to therapy is good if a long time has elapsed since initial treatment but usually not if relapse is rapid or if there is no initial response. Trisenox offers a new alternative.

Trisenox was approved as an orphan drug, a drug intended for the treatment of rare diseases or conditions. An estimated 1500 new cases of APL are diagnosed each year, of which an estimated 400 patients will not respond to, or will relapse from, first line therapy.
Arsenic-containing preparations have been in medical use for more than 2000 years. Arsenic-based therapy was used in the United States and Europe more than 100 years ago for leukemia therapy as well as for treatment of infections, but these treatments were subsequently replaced by modern chemotherapy and antibiotics. More recently, interest in arsenic-based therapy was revived by reports of the anti-leukemic activity of some traditional Chinese preparations. Chinese scientists subsequently found that the active ingredient was arsenic trioxide.

The safety and effectiveness of Trisenox were evaluated in the treatment of relapsed or refractory APL in a multicenter clinical study involving 40 patients who received arsenic trioxide infusions. Twenty- eight of the 40 patients (70%) had a remission of their leukemia and met the study-defined criteria for "response". The median time to remission was 51 days. Arsenic trioxide converts the immature cancerous white blood cells into normal white blood cells, an effect similar to that of all trans-retinoic acid. A consequence of this can be a sudden increase in the white blood cell count. In some cases the increase in white blood cells is accompanied by signs of inflammation and fluid accumulation, particularly in the lining of the heart and lungs. This is termed the "APL differentiation syndrome" and can be fatal. The usual treatment is to temporarily stop the leukemia therapy and treat with high dose steroids. In the study submitted to support the approval of Trisenox, the APL differentiation syndrome appeared in 8 of the 40 patients (20%), but in no cases was there a need to interrupt therapy with arsenic trioxide.

Trisenox can cause an important change in the electrocardiogram, an increase in what is termed the Q- T interval. An increase in the Q-T interval can in some cases lead to irregular heart rhythms that can be fatal. Significant increases of the Q-T interval appeared in 16 of the 40 patients (40%). In those patients, no serious abnormal rhythm developed (one patient had a brief episode) but the risk of the effect required that the ECG and patients be closely monitored. Other adverse effects of Trisenox are abdominal discomfort, nausea, vomiting, headache, fatigue, skin changes, and fluid accumulation. Most of the adverse effects were considered mild and resolved after therapy was completed.

In March 1998 arsenic trioxide was granted orphan designation for the treatment of patients with APL. Cell Therapeutics, Inc., will market the drug.


© 2004-2008 by unless otherwise specified

Top of Page


Search Consumer-friendly Health Sites

We have moved to Food Consumer . Org

disclaimer | advertising | jobs | privacy | about us | newsletter | Submit news/articles
link partners: | Buy Viagra | |
Buy a home | Auto Insurance | Mortgage refinancing | | Take Your Blog to a Higher Level
© Copyright 2004 - 2008 All rights reserved

Disclaimer: What's published on this website should be considered opinions of respective writers only and which has no political agenda nor commercial ambition may or may not endorse any opinion of any writer. No accuracy is guaranteed although writers are doing their best to provide accurate information only. The information on this website should not be construed as medical advice and should not be used to replace professional services provided by qualified or licensed health care workers. The site serves only as a platform for writers and readers to share knowledge, experience, and information from the scientific community, organizations, government agencies and individuals. encourages readers who have had medical conditions to consult with licensed health care providers - conventional and or alternative medical practitioners.